Talk:Programmed death-ligand 1

From Libre Pathology
Revision as of 13:16, 17 February 2018 by Michael (talk | contribs)
Jump to navigation Jump to search

Urothelial carcinoma

Urothelial carcinoma - atezolizumab[1]

Renal cell carcinoma

  • 2015 paper: ~ 15% respond to PD-L1[1]
    • Biomarkers predict response
  • 2018 paper: ~ 70% durable response among those that discontinue d/t side effects[2]
  • 2018 paper: response rates are low in UCC and RCC, current PD-L1 tests not useful in UCC and RCC[3]
  • 2018 meta-analysis: PD-L1 is a poor prognosticator in RCC (HR~2.76)[4]


References

  1. ↑ Rosenberg, JE.; Hoffman-Censits, J.; Powles, T.; van der Heijden, MS.; Balar, AV.; Necchi, A.; Dawson, N.; O'Donnell, PH. et al. (May 2016). "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.". Lancet 387 (10031): 1909-20. doi:10.1016/S0140-6736(16)00561-4. PMID 26952546.
Retrieved from "https://librepathology.org/w/index.php?title=Talk:Programmed_death-ligand_1&oldid=48632"